Olanzapine + placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Borderline Personality Disorder

Conditions

Borderline Personality Disorder

Trial Timeline

Mar 1, 2004 → Nov 1, 2005

NCT ID

NCT00091650

About Olanzapine + placebo

Olanzapine + placebo is a phase 3 stage product being developed by Eli Lilly for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00091650. Target conditions include Borderline Personality Disorder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00520507	Approved	Completed	Oct 1, 2007	May 1, 2009	Bipolar Disorder
NCT00510146	Phase 3	Completed	Aug 1, 2007	Jul 1, 2010	Depression, Bipolar
NCT00091650	Phase 3	Completed	Mar 1, 2004	Nov 1, 2005	Borderline Personality Disorder
NCT00051298	Phase 3	Completed	Nov 1, 2002	Apr 1, 2005	Schizophrenia
NCT00050206	Approved	Completed	Nov 1, 2002	May 1, 2005	Bipolar Disorder
NCT00592930	Approved	Completed	Jun 1, 2000	Dec 1, 2004	Anorexia Nervosa

Competing Products

12 competing products in Borderline Personality Disorder

See all competitors

Product	Company	Stage	Hype Score
olanzapine	Eli Lilly	Pre-clinical	23
Olanzapine	Eli Lilly	Phase 3	77
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate	Jiangsu Hengrui Medicine	Phase 2	52
Durvalumab + Tremelimumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	52
quetiapine extended-release + Placebo	AstraZeneca	Phase 3	77
Quetiapine fumarate + Placebo	AstraZeneca	Phase 2	52
Quetiapine Fumarate	AstraZeneca	Phase 3	77
ziprasidone + Placebo	Pfizer	Phase 2	51
Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin	Bristol Myers Squibb	Phase 1	32
PD-1/PD-L1 inhibitors + Chemotherapy	BeOne Medicines	Phase 2	49
Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab	Arcus Biosciences	Phase 1/2	36
vafidemstat + Placebo	Oryzon Genomics	Phase 2	44

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved